FDA Panel to Weigh Gene Therapy for Children With Sickle Cell: What’s at Stake?
SILVER SPRING, MD – An advisory committee for the U.S. Food and Drug Administration is set to review a potentially life-altering gene therapy for children with sickle cell disease, a decision that could reshape treatment for the inherited blood disorder.